Pacific Biosciences of California, Inc. Business Combination, Acquisition Related Costs
Pacific Biosciences of California, Inc. (PACB) reported Business Combination, Acquisition Related Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2026-02-25
- Pacific Biosciences of California, Inc. business combination, acquisition related costs for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Pacific Biosciences of California, Inc. business combination, acquisition related costs for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Pacific Biosciences of California, Inc. business combination, acquisition related costs for the quarter ending 2023-12-31 was $63.00K.
- Pacific Biosciences of California, Inc. business combination, acquisition related costs for the quarter ending 2023-09-30 was $8.98M.
- Pacific Biosciences of California, Inc. business combination, acquisition related costs for fiscal 2025 was $0.00.
- Pacific Biosciences of California, Inc. business combination, acquisition related costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. business combination, acquisition related costs for fiscal 2023 was $9.04M.
- Pacific Biosciences of California, Inc. business combination, acquisition related costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $9.04M derived: sum of 2 quarters · filed 2026-02-25 | $9.04M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $8.98M 10-Q · filed 2024-11-12 | $8.98M 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-17 | |||
| 2021-12-31 | $403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $31.13M derived: sum of 2 quarters · filed 2024-02-28 | $31.13M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $30.73M 10-Q · filed 2022-11-08 | $30.73M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |